Brief: Denali Therapeutics And Royalty Pharma Announce $275 Million Royalty Funding Agreement
04/12/2025 14:20
Dec 4 (Reuters) - Denali Therapeutics Inc DNLI.O: DENALI THERAPEUTICS AND ROYALTY PHARMA ANNOUNCE $275 MILLION ROYALTY FUNDING AGREEMENT DENALI THERAPEUTICS INC - ROYALTY PHARMA TO RECEIVE 9.25% ROYALTY ON WORLDWIDE SALES OF TIVIDENOFUSP ALFA FROM DENALI Source text: ID:nGNX37RwwN Further company coverage: DNLI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)